Express Scripts: Pricey PCSK9 drugs poised to 'wreak havoc'

Last week, Sanofi ($SNY) revealed a $14,600 sticker for new PCSK9 med Praluent that far exceeded the price tag analysts expected. And unsurprisingly, leading PBM and vocal price critic Express Scripts ($ESRX) is none too thrilled about it. The cost of Praluent and other next-gen cholesterol-fighters like it--such as Amgen's ($AMGN) Repatha, currently awaiting an FDA decision--could "wreak havoc" among its clients, President Tim Wentworth said on a conference call. Report | More